James Turner
Family Medicine · Washington, MONPI 1467496430
Payments from drug & device makers
Across 116 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$318
- Boehringer Ingelheim$212
- AbbVie$190
- Johnson & Johnson$188
- Amarin Pharma, Inc.$105
- Amgen$97
- plus $634 from 18 others
What the payments were for
- Food & beverage$1,743100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $318 |
| Boehringer Ingelheim | 14 | $212 |
| AbbVie(2 entities) | 9 | $190 |
| Johnson & Johnson | 14 | $188 |
| Amarin Pharma, Inc. | 7 | $105 |
| Amgen | 7 | $97 |
| Novartis | 5 | $72 |
| Boston Scientific | 1 | $66 |
| GSK | 5 | $59 |
| Pfizer | 4 | $48 |
| Merck | 3 | $46 |
| Bayer | 3 | $45 |
| Lilly USA, LLC | 3 | $41 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| AstraZeneca | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Nevro Corp. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$1,743 in reported general payments places this provider in the 70th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $4,343 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $340 |
| ClopidogrelClopidogrel Bisulfate | 17 | $245 |
| Atorvastatin Calcium | 17 | $239 |
| Gabapentin | 16 | $231 |
| Finasteride | 16 | $209 |
| Tamsulosin Hcl | 17 | $208 |
| Glimepiride | 18 | $190 |
| Hydrochlorothiazide | 26 | $156 |
| Simvastatin | 14 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet Xr | $46 | $4,34316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Washington
- Amy CouchWashington$42K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.